Clinical Trials Logo

Clinical Trial Summary

A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.


Clinical Trial Description

Eligible study participants will receive propanolol twice daily for an initial 12-week period. At the conclusion of 12-weeks, response will be assessed. Participants who achieve a complete or partial response will continue propanolol for an additional 6 weeks or 12 weeks, respectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05797662
Study type Interventional
Source AIDS Malignancy Consortium
Contact Shane McAllister, Md, Phd
Phone 612-301-2205
Email smcallis@umn.edu
Status Not yet recruiting
Phase Phase 2
Start date July 1, 2025
Completion date August 1, 2029

See also
  Status Clinical Trial Phase
Recruiting NCT04941274 - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Phase 1/Phase 2
Completed NCT03160183 - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting NCT03993106 - A Study of sEphB4-HSA in Kaposi Sarcoma Phase 2
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Completed NCT00395278 - Development of Serologic Assays for Human Herpes Virus-8
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT03296553 - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Phase 2
Recruiting NCT04305691 - Trial of Ixazomib for Kaposi Sarcoma Phase 2
Completed NCT03316274 - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma Early Phase 1
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Terminated NCT04893018 - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Phase 1
Recruiting NCT05663502 - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Not yet recruiting NCT06375122 - Natural History Study of Kaposi Sarcoma
Recruiting NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients Phase 2
Not yet recruiting NCT05411237 - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma Phase 3
Completed NCT03050788 - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma N/A
Completed NCT03404297 - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya N/A
Terminated NCT01412515 - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma Phase 2
Not yet recruiting NCT06004011 - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) N/A
Withdrawn NCT02229981 - Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma Phase 1/Phase 2